Moderna (NASDAQ:MRNA) President Stephen Hoge Sells 40,281 Shares

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 40,281 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $146.07, for a total value of $5,883,845.67. Following the transaction, the president directly owned 1,562,029 shares of the company’s stock, valued at $228,165,576.03. The trade was a 2.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22.

Moderna Stock Performance

Shares of MRNA opened at $145.62 on Thursday. The stock has a 50-day simple moving average of $96.37 and a 200-day simple moving average of $68.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock has a market capitalization of $58.14 billion, a PE ratio of -18.23 and a beta of 1.10. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $176.66.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the company posted ($2.13) earnings per share. On average, analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC boosted its stake in shares of Moderna by 17.0% during the second quarter. Integrated Wealth Concepts LLC now owns 7,653 shares of the company’s stock worth $536,000 after buying an additional 1,114 shares during the period. NewEdge Advisors LLC increased its position in Moderna by 208.0% in the 2nd quarter. NewEdge Advisors LLC now owns 4,364 shares of the company’s stock valued at $306,000 after acquiring an additional 2,947 shares during the period. Baird Financial Group Inc. raised its stake in Moderna by 149.3% during the 2nd quarter. Baird Financial Group Inc. now owns 11,918 shares of the company’s stock valued at $835,000 after acquiring an additional 7,137 shares during the last quarter. Waverly Advisors LLC purchased a new stake in Moderna during the 2nd quarter valued at approximately $243,000. Finally, Murphy Pohlad Asset Management LLC acquired a new stake in Moderna during the 2nd quarter worth approximately $268,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investor optimism is building around Moderna’s personalized cancer-vaccine program and its collaboration with Merck. Analysts see oncology as a potential long-term growth engine that could help offset weaker COVID-19 vaccine revenue and support a broader business turnaround. Speculation that Merck could acquire Moderna adds to the strategic appeal, although no transaction has been announced. Why Merck Should Buy Moderna
• Positive Sentiment: Recent coverage highlights Moderna’s strong stock recovery and investors’ growing willingness to value the company on its pipeline rather than solely on COVID-19 products. Moderna’s latest quarterly revenue also exceeded expectations, providing some support for the recovery narrative. Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
• Neutral Sentiment: Institutional ownership remains substantial, with major investors including BlackRock and California State Teachers’ Retirement System reporting sizable positions. This may improve trading support, but the cited holdings largely reflect earlier reporting periods rather than a new catalyst.
• Neutral Sentiment: Analyst opinion remains mixed: Moderna has Buy, Hold and Sell ratings, with a consensus Hold rating. This suggests investors recognize the pipeline opportunity but remain cautious about valuation, execution and the company’s path back to profitability.
• Negative Sentiment: President Stephen Hoge sold a combined 80,575 shares worth approximately $11.7 million over September 14–15. CFO James Mock also sold 34,836 shares, reducing his direct holdings by about 37%. All reported transactions were made under pre-arranged Rule 10b5-1 plans, limiting their value as discretionary bearish signals, but the insider selling could still weigh on sentiment. Moderna SEC insider-trading filing

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a report on Thursday, August 20th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Friday, August 28th. Finally, Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $40.00 to $81.00 in a research report on Thursday, September 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $76.72.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.